TP53 Gene MutationNCT07419893
Germline Genetic Testing of the TP53 Gene
An observational study of TP53 Gene Mutation and Multi-Gene Transcriptional Profiling, run by European Institute of Oncology at 1 site in Italy.
Trial summary
This is a retrospective, observational, single-center study designed as a cohort analysis. The study population will include consecutive patients referred for genetic counseling and TP53 germline genetic testing between 2004 and 2025 at the Division of Cancer Prevention and Genetics of the IEO. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- TP53 Gene Mutation, Multi-Gene Transcriptional Profiling, TP53 Gene Germline Mutation Carrier
- How many people
- 1,940 participants
- Where
- 1 siteItaly
- Study dates
- 29 Jan 2026to Jan 2031
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This is a retrospective, observational, single-center study designed as a cohort analysis. The study population will include consecutive patients referred for genetic counseling and TP53 germline genetic testing between 2004 and 2025 at the Division of Cancer Prevention and Genetics of the IEO. Participants will be stratified according to the referral criteria for genetic counseling and testing or the approach used.
Who may be able to join
- Have undergone at least one genetic counseling session at the Division of Cancer Prevention and Genetics of the IEO;
- Have undergone germline TP53 genetic testing, regardless of the referral criteria for counseling and/or testing or the approach used;
- Have provided written informed consent for participation in scientific research.
Who cannot join
- Absence of signed informed consent for participation in scientific research.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site, 1 recruiting
- Recruiting
Istituto Europeo di Oncologia
Milan, 20141
Mariarosaria Calvello, +39 0294372651, mariarosaria.calvello@ieo.it
About this study
Official title: Germline Genetic Testing of the TP53 Gene: Identification, Characterization, and Management of Patients and Families at High Risk of Cancer
This is a retrospective, observational, single-center study designed as a cohort analysis. The study population will include consecutive patients referred for genetic counseling and TP53 germline genetic testing between 2004 and 2025 at the Division of Cancer Prevention and Genetics of the IEO. The primary endpoint is to determine the overall detection rate of Pathological Variants (PVs) in the TP53 gene among individuals referred to the institute and the differences between the groups.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Individuals fulfilling the 2015 Chompret criteria. | |
| Group 2 | Individuals fulfilling the Li-Fraumeni-Like (LFL) criteria according to Birch or Eeles. | |
| Group 3 | Individuals undergoing Multi-Gene Transcriptional Profiling in the absence of Li-Fraumeni Sindrome/Li-Fraumeni-Like criteria. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall detection rate of Pathological Variants (PVs) in the TP53 gene.
To determine the overall detection rate of PVs in the TP53 gene among individuals referred to the Division of Cancer Prevention and Genetics at the IEO for TP53 genetic testing. Detection rate calculated as the number of patients with mutation of the TP53 gene divided by the total numer of patients tested.
Measured: Baseline
Secondary outcomes (5)
Detection rate of pathological variants in the TP53 gene across cohort
Fisher's exact test or Chi-squared test will be applied, as appropriate, to compare the detection rate of pathological variants in the TP53 gene between different groups.
Measured: Baseline
Detection rate of Variant of Uncertain Significance in the TP53 gene.
To determine the detection rate of Variant of Uncertain Significance (VUS) in the TP53 gene among all groups. Detection rate calculated as the number of patients with Variant of Uncertain Significance of the TP53 gene divided by the total numer of patients tested. Evaluation for potential reclassification of the detected TP53 VUS according to the 2025 ClinGen TP53 Expert Panel Specifications to the ACMG/AMP Guidelines (v2.3.0)
Measured: Baseline
Detection rate of pathological variants and variants of Uncertain Significance in other cancer susceptibility genes.
Detection rate calculated as the number of patients with a mutation of gene other than the TP53 gene divided by the total numer of patients tested.
Measured: Baseline
Disease Free Survival
To compare the Disease Free Survival l of breast cancer patients carrying pathological variants in the TP53 gene with those observed in breast cancer patients tested through Multigene Panel Testing and who did not carry pathological variants or Variants of Uncertain Significance in any of the tested genes. Disease Free Survival will be defined as the time from surgery to invasive loco-regional recurrence, metastasis, other primary non-breast carcinomas, or death from any cause, whichever occurs first.
Measured: 5 years
Overall Survival (OS)
To compare the Overall Survival of breast cancer patients carrying pathological variants in the TP53 gene with those observed in breast cancer patients tested through Multigene Panel Testing and who did not carry pathological variants or Variants of Uncertain Significance in any of the tested genes. OS will be defined as the time from surgery to death from any cause.
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2026
- Study start29 Jan 2026
- Primary completionJul 2026 (estimated)
- Study completionJan 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for TP53 Gene MutationStudies of the same condition, open and under way.
- More trials run by European Institute of OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,940 participants (estimated)
Sponsor and investigators
- Lead sponsor
- European Institute of Oncology
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07419893
- Sponsor's protocol ID
- UID 5143
- Other IDs
- L2-483
- Status last verified
- Jan 2026
- First submitted
- 2 Feb 2026
- Last updated
- 19 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Germline Genetic Testing of the TP53 Gene: Identification, Characterization, and Management of Patients and Families at High Risk of Cancer
- ClinicalTrials.gov ID
- NCT07419893
- Acronym / sponsor ID
- UID 5143
- Conditions
- TP53 Gene Mutation, Multi-Gene Transcriptional Profiling, TP53 Gene Germline Mutation Carrier
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,940 participants (estimated)
- Lead sponsor
- European Institute of OncologyUniversity, hospital or other
- Study start
- 29 Jan 2026 (actual)
- Primary completion
- Jul 2026 (estimated)
- Study completion
- Jan 2031 (estimated)
- First posted
- 19 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a retrospective, observational, single-center study designed as a cohort analysis. The study population will include consecutive patients referred for genetic counseling and TP53 germline genetic testing between 2004 and 2025 at the Division of Cancer Prevention and Genetics of the IEO. The primary endpoint is to determine the overall detection rate of Pathological Variants (PVs) in the TP53 gene among individuals referred to the institute and the differences between the groups.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Group 1 | – | –Individuals fulfilling the 2015 Chompret criteria. |
| Group 2 | – | –Individuals fulfilling the Li-Fraumeni-Like (LFL) criteria according to Birch or Eeles. |
| Group 3 | – | –Individuals undergoing Multi-Gene Transcriptional Profiling in the absence of Li-Fraumeni Sindrome/Li-Fraumeni-Like criteria. |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This is a retrospective, observational, single-center study designed as a cohort analysis. The study population will include consecutive patients referred for genetic counseling and TP53 germline genetic testing between 2004 and 2025 at the Division of Cancer Prevention and Genetics of the IEO. Participants will be stratified according to the referral criteria for genetic counseling and testing or the approach used.
Key inclusion criteria (3 listed)
- Have undergone at least one genetic counseling session at the Division of Cancer Prevention and Genetics of the IEO;
- Have undergone germline TP53 genetic testing, regardless of the referral criteria for counseling and/or testing or the approach used;
- Have provided written informed consent for participation in scientific research.
Key exclusion criteria (1 listed)
- Absence of signed informed consent for participation in scientific research.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall detection rate of Pathological Variants (PVs) in the TP53 gene.
Time frame: Baseline
To determine the overall detection rate of PVs in the TP53 gene among individuals referred to the Division of Cancer Prevention and Genetics at the IEO for TP53 genetic testing. Detection rate calculated as the number of patients with mutation of the TP53 gene divided by the total numer of patients tested.
5 secondary outcomes
Detection rate of pathological variants in the TP53 gene across cohort
Time frame: Baseline
Detection rate of Variant of Uncertain Significance in the TP53 gene.
Time frame: Baseline
Detection rate of pathological variants and variants of Uncertain Significance in other cancer susceptibility genes.
Time frame: Baseline
Disease Free Survival
Time frame: 5 years
Overall Survival (OS)
Time frame: 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Feb 2026.
Related trials for TP53 Gene Mutation
Not yet recruitingPhase 1
ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
RecruitingPhase 3
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Not yet recruiting
Reduce All Avoidable Cancer-promoting Exposures in Individuals at High Genetic Risk of Cancer Carrying a Constitutional Variant of the TP53 Gene
Adult Carriers of a Pathogenic or Probably Pathogenic (Class 4 and 5) Germline Variation in the TP53 Gene
RecruitingObservational study
Clinical and Genetic Studies of Li-Fraumeni Syndrome
Li-Fraumeni Syndrome, Neoplasms
RecruitingPhase 1/2
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of TP53 Gene Mutation and Multi-Gene Transcriptional Profiling, run by European Institute of Oncology at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mariarosaria Calvello, MD (+39 0294372651, mariarosaria.calvello@ieo.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall detection rate of Pathological Variants (PVs) in the TP53 gene. (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Feb 2026.